Free Trial

Hypermarcas (OTCMKTS:HYPMY) Shares Gap Down - Here's Why

Hypermarcas logo with Medical background

Key Points

  • Hypermarcas' stock price gapped down from $4.60 to $4.35 prior to trading on Wednesday, with a trading volume of 378 shares.
  • Scotiabank upgraded Hypermarcas to a "strong-buy" rating, contributing to an average rating of "Strong Buy" among analysts.
  • The company reported a quarterly earnings per share of $0.12 and has a market capitalization of $2.76 billion.
  • MarketBeat previews the top five stocks to own by November 1st.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $4.60, but opened at $4.35. Hypermarcas shares last traded at $4.35, with a volume of 378 shares.

Analyst Upgrades and Downgrades

Separately, Scotiabank upgraded Hypermarcas to a "strong-buy" rating in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Strong Buy".

View Our Latest Report on Hypermarcas

Hypermarcas Stock Down 5.4%

The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $2.76 billion, a P/E ratio of 20.72 and a beta of 0.86. The firm has a 50 day simple moving average of $4.44 and a two-hundred day simple moving average of $4.21.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

About Hypermarcas

(Get Free Report)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Hypermarcas Right Now?

Before you consider Hypermarcas, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.

While Hypermarcas currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.